Stable Angina Medical Services in China

Stable angina pectoris is a chronic manifestation of coronary artery disease characterized by predictable, transient chest discomfort—typically described as pressure, tightness, or squeezing—triggered by physical exertion or emotional stress and relieved within minutes by rest or nitroglycerin. It results from myocardial ischemia due to fixed atherosclerotic stenosis in one or more epicardial coronary arteries, without acute myocardial necrosis. Diagnosis relies on clinical history, electrocardiography (ECG), stress testing (e.g., exercise treadmill test, myocardial perfusion imaging), and confirmatory coronary angiography. Management emphasizes risk factor modification (hypertension, dyslipidemia, diabetes, smoking cessation), anti-ischemic pharmacotherapy (beta-blockers, calcium channel blockers, nitrates), and secondary prevention with dual antiplatelet therapy and high-intensity statins. In select cases, revascularization—either percutaneous coronary intervention (PCI) with drug-eluting stents or coronary artery bypass grafting (CABG)—is indicated to improve symptoms and quality of life.

China offers distinct advantages for stable angina management: its cardiovascular centers feature internationally trained interventional cardiologists and cardiac surgeons certified by the Chinese Society of Cardiology and accredited by the European Society of Cardiology. Hospitals deploy state-of-the-art equipment—including intravascular ultrasound (IVUS), optical coherence tomography (OCT), and fractional flow reserve (FFR) guidance—to optimize stent placement and long-term outcomes. Over 95% of elective PCI procedures achieve procedural success with low major adverse cardiac event (MACE) rates at one year. Treatment costs are typically 40–60% lower than in the US, UK, or Germany, without compromising clinical standards or regulatory oversight. As a dedicated medical tourism agency, we facilitate seamless care for international patients—vetting JCI-accredited hospitals, coordinating appointments with top-tier specialists, providing transparent, all-inclusive pricing, and offering end-to-end support including visa assistance, medical translation, accommodation, and post-treatment follow-up.

Treatment Options & Itemized Cost Breakdown: Stable Angina Pectoris (Cardiology Department)

I. Non-Surgical / Conservative Management

*Target Criteria:* CCS Class I–II angina, low-to-intermediate SYNTAX score (<22), no high-risk features (e.g., LVEF <40%, recent decompensation).

• •Core Medications (Monthly, USD):

- High-intensity statin (e.g., atorvastatin 40 mg): $3.80 - Beta-blocker (e.g., metoprolol SR 50–100 mg): $2.50 - Long-acting nitrates (e.g., isosorbide mononitrate 30–60 mg): $4.10 - Optional: Ranolazine (500 mg BID) — $28.60/month

• •Essential Diagnostic Monitoring (One-Time, USD):

- Transthoracic echocardiogram (TTE): $42.00 - Fasting lipid panel + HbA1c + renal function: $26.00 - Stress testing (exercise ECG or pharmacologic stress echo): $115.00–$185.00

II. Surgical / Interventional Options

*Eligibility Criteria:* Refractory CCS Class III–IV despite ≥3 optimized medications; anatomically suitable lesions (e.g., single-vessel proximal LAD stenosis ≥70%, multivessel disease with SYNTAX score ≥22 or left main disease).

• •Percutaneous Coronary Intervention (PCI):

- PCI with 1 drug-eluting stent (DES): $4,200–$5,800 - PCI with 2–3 DES: $5,900–$7,600 - *Includes: catheterization, stent deployment, post-procedure monitoring (24h)*

• •Coronary Artery Bypass Grafting (CABG):

- Off-pump CABG (3 grafts): $12,400–$14,900 - On-pump CABG (3–4 grafts): $15,200–$18,700 - *Includes: ICU stay (2 days), surgical team, anesthesia, graft materials, 5-day ward stay*

III. Special/Complex Condition Management

• •Diabetic patients with multivessel disease: Prioritize CABG over PCI (superior 5-year survival); add SGLT2 inhibitor (empagliflozin): $24.50/month
• •Severe chronic kidney disease (eGFR <30 mL/min): Avoid iodinated contrast; use IVUS-guided PCI or conservative strategy; dialysis-adjusted anticoagulation adds $180.00/session
• •Elderly (>80 years) with frailty: Frailty assessment (gait speed, grip strength) — $35.00; prefer single-vessel PCI or intensified medical therapy

IV. Quick Selection Guide

• •<65 years, moderate angina, no diabetes/CKD: Start with optimized medical therapy ($45–$65/month) + stress echo ($115) → escalate to 1-stent PCI ($4,200) if refractory
• •65–75 years, multivessel disease, diabetes: Proceed directly to CABG ($15,200) — cost-effective long-term revascularization
• •>75 years, frail, limited life expectancy: Focus on symptom-limited medical therapy ($55/month) + ranolazine ($28.60) — avoid procedural risks
• •Budget-constrained (<$2,000 total): Full medical optimization + exercise-based cardiac rehab ($120/course) — proven mortality benefit without procedure costs